1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Panion & BF Biotech Inc.

Panion & BF Biotech Inc.

TTWSE:1760
51.70
TWD
-0.80
(-1.52%)
2.51EPS
24.28P/E
5.22BMarket Cap
Nov 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.25
14.85
17.46
15.18
17.54
18.19
20.21
20.14
24.01
27.98
21.95
23.67
24.07
24.62
Basic EPS, GAAP
0.3
0.71
1.06
1.3
1.31
2.06
2.07
0.36
1.32
2.13
0.9
1.45
2.22
2.51
Free Cash Flow per Basic Share
1.11
0.04
-0.09
1.55
1.28
0.51
-0.27
-1.49
2.92
3.4
-0.04
1.93
1.76
2.29
Dividend per Share
- -
- -
0.11
0.65
0.81
1.49
1.77
1.77
0.68
1.5
2
1.5
1.8
- -
Book Value per Share
9.64
10.39
11.22
11.66
12.08
17.34
17.46
15.92
22.55
23.41
22.29
22.42
22.8
21.86
Tangible Book Value per Share
9.5
10.22
11.08
11.53
11.96
17.24
17.37
15.62
22.32
23.22
22.15
22.32
22.63
21.7
Basic Weighted Avg Shares
60
68
69
69
69
77
78
78
79
86
86
86
86
86
Sales/Revenue/Turnover
857
1,014
1,205
1,049
1,212
1,409
1,574
1,569
1,901
2,399
1,882
2,030
2,063
2,109
Operating Margin (%)
1.62
6.35
9.96
12.35
11.94
15.05
14.23
8.09
8.81
17.26
8.28
10.6
14.96
15.11
Depreciation Expense
23
26
33
42
42
41
68
84
144
164
170
164
138
136
Net Income, GAAP
18
48
73
90
91
159
161
28
104
182
77
125
190
215
Effective Tax Rate (%)
32.53
36.33
37.17
30.68
36.75
34.87
28.71
68.79
42.84
45.31
54.23
42.73
35.32
32.77
Profit Margin (%)
2.12
4.76
6.06
8.55
7.47
11.3
10.25
1.78
5.49
7.6
4.1
6.14
9.22
10.19
Working Capital
350
343
369
375
429
927
838
508
534
478
426
483
457
356
LT Debt
- -
- -
- -
- -
- -
- -
85
744
168
58
148
153
158
126
Total Equity
657
711
775
806
835
1,350
1,360
1,240
1,933
2,007
1,911
1,922
1,955
1,874
Return on Invested Capital (%)
1.45
5.86
9.92
11.14
11.01
12.49
11.21
1.93
3.82
9.13
2.78
4.68
7.61
8.57
Return on Capital (%)
3.81
7.17
9.82
11.38
11.04
14.57
11.53
1.47
4.56
7.57
3.21
5.06
7.63
9.03
Return on Common Equity (%)
3.96
7.06
9.83
11.35
11.03
14.56
11.91
2.15
6.58
9.26
3.94
6.5
9.81
11.63

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
490
479
478
LT Borrowings
131
118
105
LT Finance Leases
27
25
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
86
86
86
Market Capitalization
5,402
5,333
5,222

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,467
1,449
1,471
Cash, Cash Equivalents & STI
460
452
471
Accounts Receivable, Net
225
206
220
Inventories
568
563
571
Total Current Liabilities
1,010
1,129
1,115
Payables & Accruals
- -
- -
- -
ST Debt
490
479
478
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.84%
11.44%
1.69%
Free Cash Flow
-639.7%
-964.81%
-8.62%
Net Income, GAAP
42.35%
81.04%
52.72%
Sales/Revenue/Turnover
6.55%
7.07%
1.66%
Total Cash Common Dividend
- -
21.33%
20%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
499
506
501
523
2,030
2025
482
504
532
546
2,063
2026
519
512
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.51
0.23
0.32
0.38
1.45
2025
0.33
0.44
0.88
0.57
2.22
2026
0.6
0.46
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.5
2025
- -
- -
- -
- -
1.8
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tsung Ming Chiang
Full Time Employees
321
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 3, Yuanqu Street Taipei TP Taiwan 11503
IPO Date
Jan 23, 2018
Website
pbf.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Panion & Bf Biotech Inc. is a biotechnology pharmaceutical company primarily engaged in the development, manufacturing, and sale of western medicines, cosmetics, and health care products. The company offers a comprehensive range of products including antibody drugs, respiratory drugs, gastrointestinal drugs, Covid-19 in vitro diagnostics (IVD), antigens, anti-aging products, active pharmaceutical ingredients (APIs), disease treatment and prevention drugs, and veterinary products. Additionally, Panion & Bf Biotech provides nephrology, dermatology, pain management, hospital and household sanitization, and personal hygiene services. The company operates in Taiwan, the United States, China, Hong Kong, and international markets. Founded in 1974, it is headquartered in Taipei, Taiwan. Recent major developments include the launch of PxoBang, a novel aesthetic and regenerative treatment product combining exosome and platelet-rich plasma (PRP) technology with patented stability technology; PxoBang has demonstrated clinical effectiveness in reducing fine lines, facial pores, and supporting skin regeneration. Panion & Bf Biotech also actively participates in international conferences to promote its innovative cosmetic and pharmaceutical technologies, while seeking exclusive distribution partnerships for its advanced products. The company maintains a strong focus on advanced research and product development to enhance its cosmetic and pharmaceutical portfolio. These strategic product innovations and international outreach activities mark significant growth and operational expansion within the last two years.